Transfusion dependent beta-thalassemia. Transfusion dependent beta-thalassemia
Conditions
Interventions
Intervention 1: Intervention group: The N-Acethyl Cystein Group. Intervention 2: Intervention group: ?The vitamin E group. Intervention 3: Control group: No treatment.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients with transfusion-dependent beta-thalassemia above 18 years old who were diagnosed by clinical history, and hemoglobin electrophoresis. Receiving regular blood transfusion (15 cc/kg body weight with interval of 3-4 weeks to maintain hemoglobin levels above 9.5 g/dl) Treating by at least one or combination of iron chelation therapy agents including deferasirox (DFX), deferiprone (DFP), and deferoxamine (DFO).
Exclusion criteria
Exclusion criteria: No desire to participate in the study Being positive for hepatitis B, C or HIV Pregnancy Presentation of any acute infectious disease Narcotic addiction Under treatment with nitroglycerine or other related drugs Asthma Known allergy to NAC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum total oxidant status (TOS). Timepoint: At baseline and at the end of the study. Method of measurement: Blood sampling and using specific kit.;Total antioxidant capacity (TAC). Timepoint: At baseline and at the end of the study. Method of measurement: Blood sampling and using specific kit.;Hemoglobin levels. Timepoint: At baseline and at the end of the study. Method of measurement: Blood sampling.;Serum ferritin levels. Timepoint: At the beginning of the study and after three months. Method of measurement: Blood sampling. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug adverse events. Timepoint: Monthly. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSezaneh Haghpanah
Shiraz University of Medical Sciences
Outcome results
None listed